Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
depression
Biotech
Actinogen reports new data in bid to salvage depression drug
Xanamem missed its phase 2 primary endpoint in cognitive function, but new data show that the compound has hit secondary endpoints in depression.
Darren Incorvaia
Aug 26, 2024 11:03am
Actinogen's cortisol blocker fails phase 2 depression study
Aug 12, 2024 10:05am
J&J's oral add-on aces phase 3 in major depressive disorder
May 29, 2024 11:55am
NRx keeps antidepressant's blockbuster hopes alive despite flop
Apr 30, 2024 11:16am
Karuna's captains set sail in new neuropsychiatric biotech
Apr 9, 2024 8:25am
FDA clears Otsuka, Click's prescription app for depression
Apr 3, 2024 1:53pm